Payment overview · 2025
General Payments
$534.81
27 reported records · 16 companies
Healthcare provider profile · identity verified
John Clark Hill, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COMMERCE, GA · NPI 1174587588
Verified facts
What the public records show
CMS Open Payments records show John Clark Hill, MD received $534.81 in general payments during 2025 across 27 reported records.
Novo Nordisk Inc accounted for 14.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Ozempic, Rybelsus, Shingrix, Trelegy Ellipta, Trintellix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 681 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.76 | 14.3% | 4 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $62.01 | 11.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.61 | 11.2% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $50.53 | 9.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $42.11 | 7.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.41 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.15 | 7.0% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $22.76 | 4.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.04 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.36 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.58 | 3.5% | 1 | 2025 |
| Krystal Biotech Inc | Unresolved — no canonical attribution shown | $18.11 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.27 | 3.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.22 | 3.2% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $16.99 | 3.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.90 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $534.81 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.76 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $62.01 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.61 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.58 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $50.53 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.15 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| VYJUVEK Normalized: vyjuvek |
Drug | Krystal Biotech Inc | $18.11 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 30 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
169 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
681 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1446 | 130 |
| Gabapentin | Gabapentin | 1392 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1355 | 146 |
| Furosemide | Furosemide | 1274 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 1162 | 161 |
| Lisinopril | Lisinopril | 1099 | 166 |
| Metoprolol Tartrate | Metoprolol Tartrate | 965 | 90 |
| Potassium Chloride | Potassium Chloride | 928 | 86 |
| Atorvastatin Calcium | Atorvastatin Calcium | 900 | 190 |
| Tamsulosin Hcl | Tamsulosin Hcl | 849 | 105 |
| Omeprazole | Omeprazole | 770 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 742 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 687 | 140 |
| Eliquis | Apixaban | 681 | 58 |
| Losartan Potassium | Losartan Potassium | 594 | 87 |
| Buspirone Hcl | Buspirone Hcl | 581 | 62 |
| Famotidine | Famotidine | 579 | 72 |
| Donepezil Hcl | Donepezil Hcl | 569 | 64 |
| Mirtazapine | Mirtazapine | 560 | 59 |
| Fluoxetine Hcl | Fluoxetine Hcl | 541 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 498 | 46 |
| Memantine Hcl | Memantine Hcl | 484 | 35 |
| Metformin Hcl | Metformin Hcl | 458 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 412 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 402 | 72 |
| Trazodone Hcl | Trazodone Hcl | 400 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 374 | 39 |
| Sertraline Hcl | Sertraline Hcl | 363 | 42 |
| Allopurinol | Allopurinol | 358 | 43 |
| Atenolol | Atenolol | 340 | 66 |
| Carvedilol | Carvedilol | 340 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 327 | 26 |
| Divalproex Sodium | Divalproex Sodium | 320 | 21 |
| Montelukast Sodium | Montelukast Sodium | 287 | 68 |
| Tramadol Hcl | Tramadol Hcl | 279 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 278 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 277 | 48 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 277 | 17 |
| Meloxicam | Meloxicam | 275 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 256 | 30 |
| Clonazepam | Clonazepam | 245 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 55 |
| Simvastatin | Simvastatin | 217 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 215 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 214 | 20 |
| Lorazepam | Lorazepam | 213 | 55 |
| Rexulti | Brexpiprazole | 210 | 11 |
| Finasteride | Finasteride | 201 | 18 |
| Risperidone | Risperidone | 195 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 195 | 30 |
| Nifedipine Er | Nifedipine | 192 | suppressed |
| Myrbetriq | Mirabegron | 188 | 14 |
| Glipizide Er | Glipizide | 186 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 174 | 20 |
| Ezetimibe | Ezetimibe | 172 | 29 |
| Januvia | Sitagliptin Phosphate | 171 | 20 |
| Brilinta | Ticagrelor | 169 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 167 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 166 | 23 |
| Ozempic | Semaglutide | 164 | 32 |
| Levetiracetam | Levetiracetam | 158 | 19 |
| Alprazolam | Alprazolam | 153 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 43 |
| Paroxetine Hcl | Paroxetine Hcl | 152 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 140 | 49 |
| Spironolactone | Spironolactone | 140 | 25 |
| Torsemide | Torsemide | 137 | 11 |
| Pregabalin | Pregabalin | 134 | 20 |
| Xarelto | Rivaroxaban | 134 | 11 |
| Alendronate Sodium | Alendronate Sodium | 132 | 33 |
| Calcitriol | Calcitriol | 128 | suppressed |
| Dutasteride | Dutasteride | 123 | 13 |
| Metolazone | Metolazone | 122 | suppressed |
| Novolog Flexpen | Insulin Aspart | 122 | 24 |
| Bupropion Xl | Bupropion Hcl | 116 | 18 |
| Methylprednisolone | Methylprednisolone | 113 | 94 |
| Jardiance | Empagliflozin | 111 | 20 |
| Olanzapine | Olanzapine | 107 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 106 | suppressed |
| Sucralfate | Sucralfate | 106 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 96 | 15 |
| Linzess | Linaclotide | 95 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 91 | suppressed |
| Baclofen | Baclofen | 89 | suppressed |
| Topiramate | Topiramate | 88 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 86 | suppressed |
| Glipizide | Glipizide | 83 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 82 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 76 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 75 | suppressed |
| Febuxostat | Febuxostat | 74 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 46 |
| Latanoprost | Latanoprost | 73 | suppressed |
| Fenofibrate | Fenofibrate | 72 | 14 |
| Lovastatin | Lovastatin | 72 | 18 |
| Memantine Hcl Er | Memantine Hcl | 69 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 66 | 12 |
| Cephalexin | Cephalexin | 62 | 41 |
| Chlorthalidone | Chlorthalidone | 62 | suppressed |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 60 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 19 |
| Sotalol | Sotalol Hcl | 60 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 57 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 56 | suppressed |
| Rybelsus | Semaglutide | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 55 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 54 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 52 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 12 |
| Estradiol | Estradiol | 51 | 14 |
| Lacosamide | Lacosamide | 51 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 50 | suppressed |
| Temazepam | Temazepam | 50 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 50 | suppressed |
| Azithromycin | Azithromycin | 49 | 42 |
| Diazepam | Diazepam | 49 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 49 | suppressed |
| Celecoxib | Celecoxib | 47 | 13 |
| Mesalamine | Mesalamine | 47 | suppressed |
| Phenobarbital | Phenobarbital | 47 | suppressed |
| Roflumilast | Roflumilast | 47 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 47 | suppressed |
| Primidone | Primidone | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Nystatin | Nystatin | 43 | 33 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 42 | 14 |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 41 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Oxycontin | Oxycodone Hcl | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 28 |
| Brimonidine Tartrate | Brimonidine Tartrate | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 28 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 27 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 32 | suppressed |
| Prednisone | Prednisone | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 25 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | 12 |
| Levemir Flexpen | Insulin Detemir | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 24 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 28 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Naproxen | Naproxen | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nystop | Nystatin | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 16 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Ketoconazole | Ketoconazole | 21 | 12 |
| Metformin Er Gastric | Metformin Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 16 |
| Minocycline Hcl | Minocycline Hcl | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Admelog Solostar | Insulin Lispro | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.81 · 27 records | Novo Nordisk Inc | AREXVY, Auvelity, BREZTRI, CRYSVITA, Dexcom G6 Transmitter, FANAPT, GVOKE HYPOPEN, Heplisav-B, Hizentra, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRINTELLIX, VYJUVEK, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error